Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?

Gastrointest Endosc. 2010 Dec;72(6):1330; author reply 1330-2. doi: 10.1016/j.gie.2010.03.1073.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Capecitabine
  • Colonic Diseases / chemically induced*
  • Colonic Diseases / therapy*
  • Colorectal Neoplasms / therapy*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Drug-Related Side Effects and Adverse Reactions
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives
  • Humans
  • Intestinal Obstruction / therapy*
  • Intestinal Perforation / chemically induced*
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / adverse effects
  • Oxaliplatin
  • Rupture, Spontaneous
  • Stents*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Organoplatinum Compounds
  • Oxaliplatin
  • Deoxycytidine
  • Bevacizumab
  • Capecitabine
  • Fluorouracil